A Phase I, Randomized, Double-blind, Placebo-controlled, Dose-ascending Study to Evaluate the Pharmacokinetics, Immunogenicity, Safety, and Tolerability of MEDI3506 in Healthy Chinese Participants
Latest Information Update: 17 Feb 2022
At a glance
- Drugs Tozorakimab (Primary)
- Indications Asthma; Atopic dermatitis; Chronic obstructive pulmonary disease; COVID 2019 infections; Diabetic nephropathies
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 14 Feb 2022 Status changed from active, no longer recruiting to completed.
- 16 Nov 2021 Planned End Date changed from 14 Jan 2022 to 30 Jan 2022.
- 16 Nov 2021 Planned primary completion date changed from 14 Jan 2022 to 30 Jan 2022.